Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort

作者：Janzic U, Shalata W, Unk M, Terglav AS, Shirron N, Daher S, Moskovitz M, Merimsky O, Garrido P, Lopes M, Araujo D, Shantzer T, Gantz-Sorotsky H, Rotem O, Urban D, Chmielewska I, Barroso A, Zer A · 发表于：Frontiers in oncology · 年份：2026 · DOI：10.3389/fonc.2026.1821628 · 被引用次数：33

PURPOSE: To describe real-world treatment patterns and outcomes among patients with extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus durvalumab as in CASPIAN trial within Expanded Access Program, with a focus on the use and impact of consolidation (cRT) and salvage radiotherapy (sRT). PATIENTS AND METHODS: This retrospective, multicenter cohort study included patients with ES-SCLC treated with durvalumab plus platinum-etoposide between September 2019 and December 2022 across 11 academic centers in Israel, Poland, Portugal, and Slovenia. Patients characteristics, radiotherapy use, adverse events (AE), and outcomes were collected using a standardized form. Radiotherapy was categorized as cRT, sRT, or palliative RT (pRT). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods and compared using log-rank testing. Multivariable Cox regression evaluated predictors of survival. RESULTS: A total of 133 patients were included (median age 65 years; 74% ECOG PS 0-1). Radiotherapy was administered to 58.6% of patients (cRT 28.2%, sRT 24.3%, pRT 47.4%). Median (m) PFS and mOS for the entire cohort were 6.9 months (m) and 15.9 m, respectively. Patients receiving cRT achieved the longest mPFS (11.7 m) and a mOS of 19.5 m; sRT was associated with an mOS of 20.4 m. Continuation of durvalumab beyond progression combined with RT was associated with improved survival (p = 0.024). Treatment-related AEs occurr...